Last reviewed · How we verify
NCT07106931: START
Early STratification of Acute ARThritis
trial testing This is an observational study with no intervention in Arthritis in 400 participants. Currently enrolling.
31 December 2044
Quick facts
| Lead sponsor | Diakonhjemmet Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 5 November 2024 |
| Primary completion | 31 December 2044 |
| Estimated completion | 31 December 2044 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- This is an observational study with no intervention
Conditions studied
- Arthritis — all drugs for Arthritis →
Sponsor
Diakonhjemmet Hospital
Who can join
18 and older, any sex, with Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The prospective observational study "Early STratification of acute inflammatory ARThritis" (START) aims to build a platform for identification of markers for early stratification of inflammatory arthritis to ensure timely diagnosis and correct initial treatment. Management of early-stage inflammatory arthritis is a daily challenge for the rheumatologist and encompasses a range of conditions. Stratification is needed both for optimal diagnostics and for personalising therapy, but is hampered by a lack of tools. Current evaluation is inadequate for early diagnosis and treatment of inflammatory joint diseases as well as for timely diagnosis of infections. The clinical role of novel biomarkers needs to be investigated in large patient samples. In the START study, an extensive data collection will be performed to build a platform for identification and validation of biomarkers for stratification of early-stage inflammatory arthritis. The study has an ambitious goal of improving patient care by increased understanding of the disease. The project applies a unique multitude of approaches to characterisation of patients, including modern imaging techniques, analyses of synovial fluid and -biopsies, genetic and epigenetic markers, proteomics, microbiota analyses and immunological markers. The results will enable clinicians to make better informed treatment decisions for the individual patient with early-stage inflammatory arthritis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07106931
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Arthritis
Currently open trials in the same condition.
- NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature · recruiting
- NCT07284563 — Ultralow Dose PET Imaging for 18F-NaF Uptake · Phase 2 · recruiting
- NCT06915012 — Impact of Biophoton Therapy on Chronic Severe Arthritis Pain · NA · recruiting
- NCT06880653 — Dose Response of Exercise for Arthritis Management · NA · recruiting
- NCT06257537 — Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis · Phase 2 · recruiting
Other Diakonhjemmet Hospital trials
Trials by the same sponsor.
- NCT07003932 — Remote Monitoring After Total Knee Replacement · NA · recruiting
- NCT06656845 — Feasibility of a Self-management App for People With Knee Osteoarthritis (OA-AID Feasibility Study) · NA · completed
- NCT06440629 — Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Ar · Phase 4 · recruiting
- NCT06281184 — A 30-month Follow-up of MERINO Participants to Evaluate Long-term Effects of Methotrexate in Erosive Hand OA. · enrolling by invitation
- NCT06462937 — A Digital Exercise Intervention in Patients With Spondyloarthritis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07106931 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Diakonhjemmet Hospital
- Last refreshed: 6 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07106931.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing